Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

wherein one of R^1 and R^2 represents hydrogen atom and the other represents the formula -X-A wherein A represents hydrogen atom or an acyl group, X represents oxgen atom or NH; one of R^3 and R^4 represents hydrogen atom and the other represents the following formula:



wherein Y represents a sulfonyl group or a carbonyl group, R^5 represents a cyclic group which may be substituted, Z represents a single bond or a C_1 to C_4 alkylene group which may be substituted, or when Z is substituted, said substituent may bind to R^5 to form a ring group, R^6 represents hydrogen atom or a C_1 to C_6 alkyl group which may be

substituted, or R^6 may bind to Z or R^5 to form a cyclic group, provided that a compound represented by the following formula:



wherein each of A, Z, R^5 and R^5 has the same meaning as that defined above is excluded.

2. (Original) The medicament according to claim 1, wherein R^5 is an aromatic ring group which may be substituted.

3. (Previously Presented) The medicament according to claim 1, wherein Z is a methylene group which may be substituted, or when Z is substituted, said substituent may bind to R^5 to form a ring group.

4. (Previously Presented) The medicament according to claim 1, wherein Y is a sulfonyl group.

5. (Previously Presented) The medicament according to claim 1, wherein R^1 is a group represented by the formula -O-A wherein A represents hydrogen atom or an acyl group, and R^2 is hydrogen atom.

6. (Previously Presented) The medicament according to claim 1, wherein the cancer therapy based on the mode of action of DNA injury is carried out by an administration of an anticancer agent and/or radiation.

7. (Original) The medicament according to claim 6, wherein the anticancer agent is selected from the group consisting of bleomycin, adriamycin, cisplatin, cyclophosphamide, mitomycinC, and a derivative thereof.

8. (Previously Presented) The medicament according to claim 1, which is a specific inhibitor of a protein kinase and/or an analogous enzyme thereof.

9. (Original) A medicament for reducing a side effect resulting from a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof according to claim 1.

10. (Currently amended) A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof according to claim 1, provided that the following ~~compound is~~ compounds are excluded[[.]] :











11. (Original) A compound selected from the group consisting of the following compounds or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.

N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-

sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Dihydroxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,5-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Methylenedioxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Cyclohexylmethyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Phenyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-(3,4-Dihydroxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,3-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3,5-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3,4-Methylenedioxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-Cyclohexylmethyl-5-hydroxynaphthalene-1-sulfonamide;

N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;

5-Acetyloxy-N-benzylnaphthalene-2-sulfonamide;

5-Acetyloxy-N-(2,4-dichlorobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(3-nitrobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(3-aminobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(1-naphthylmethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-[(pyridin-2-yl)methyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-(cyclohexylmethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-phenylnaphthalene-2-sulfonamide;

5-Acetyloxy-N-(2-phenethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(1-phenethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-benzyl-N-methylnaphthalene-2-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;

N-(Cyclohexylmethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;

5-Acetylamino-N-benzylnaphthalene-2-sulfonamide;

5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;

5-Amino-N-benzylnaphthalene-2-sulfonamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;

6-Acetylamino-N-benzylnaphthalene-1-sulfonamide;

6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;

6-Amino-N-benzylnaphthalene-1-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;

6-Acetylamino-N-benzylnaphthalene-2-sulfonamide;

6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

6-Amino-N-benzylnaphthalene-2-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzylnaphthalene-1-carboxamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide;

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

12. (Previously Presented) A medicament which comprises as an active ingredient a substance selected from the group consisting of a compound and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof according to claim 10.

13. (Original) A medicament according to claim 12, which is used for enhancing an effect of a cancer therapy based on a mode of action of DNA injury.

14. (New) The medicament according to claim 2, wherein Z is a methylene group which may be substituted, or when Z is substituted, said substituent may bind to R^5 to form a ring group.

15. (New) The medicament according to claim 2, wherein Y is a sulfonyl group.

16. (New) The medicament according to claim 2, wherein R^1 is a group represented by the formula –O-A wherein A represents hydrogen atom or an acyl group, and R^2 is hydrogen atom.

17. (New) The medicament according to claim 2, wherein R^5 is a substituted phenyl group.

18. (New) The medicament according to claim 2, wherein the substance is selected from the group consisting of the following compounds.

N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Dihydroxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Methoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,5-Dimethoxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3,4-Methylenedioxybenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Phenyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2,6-Difluorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(4-Nitrobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Methylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[2-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-(3,4-Dihydroxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Methoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(2,3-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3,5-Dimethoxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3,4-Methylenedioxylbenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(3-Aminobenzyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Dimethylamino)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[4-(Methanesulfonyl)benzyl]-5-hydroxynaphthalene-1-sulfonamide;

N-(1-Naphthylmethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-[(Benzimidazol-2-yl)methyl]-5-hydroxynaphthalene-1-sulfonamide;

N-Phenyl-5-hydroxynaphthalene-1-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-(1-Phenethyl)-5-hydroxynaphthalene-1-sulfonamide;

N-Benzyl-N-methyl-5-hydroxynaphthalene-1-sulfonamide;

5-Acetyloxy-N-benzylnaphthalene-2-sulfonamide;

5-Acetyloxy-N-(2,4-dichlorobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(3-nitrobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-[4-(trifluoromethyl)benzyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(3-aminobenzyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(1-naphthylmethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-[(5-methylfuran-2-yl)methyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-[(pyridin-2-yl)methyl]naphthalene-2-sulfonamide;

5-Acetyloxy-N-phenylnaphthalene-2-sulfonamide;

5-Acetyloxy-N-(2-phenethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-(1-phenethyl)naphthalene-2-sulfonamide;

5-Acetyloxy-N-benzyl-N-methylnaphthalene-2-sulfonamide;

N-Benzyl-5-hydroxynaphthalene-2-sulfonamide;

N-(2,4-Dichlorobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(3-Nitrobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-[4-(tert-Butyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;

N-[4-(Trifluoromethyl)benzyl]-5-hydroxynaphthalene-2-sulfonamide;

N-(2,3-Dimethoxybenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(3-Aminobenzyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(1-Naphthylmethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-[(5-Methylfuran-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;

N-[(Pyridin-2-yl)methyl]-5-hydroxynaphthalene-2-sulfonamide;

N-Phenyl-5-hydroxynaphthalene-2-sulfonamide;

N-(2-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-(1-Phenethyl)-5-hydroxynaphthalene-2-sulfonamide;

N-Benzyl-N-methyl-5-hydroxynaphthalene-2-sulfonamide;

5-Acetylamino-N-benzylnaphthalene-2-sulfonamide;

5-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Acetylamino-N-benzyl-N-methylnaphthalene-2-sulfonamide;

5-Amino-N-benzylnaphthalene-2-sulfonamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzyl-N-methylnaphthalene-2-sulfonamide;

6-Acetylamino-N-benzylnaphthalene-1-sulfonamide;

6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;

6-Amino-N-benzylnaphthalene-1-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-sulfonamide;

6-Acetylamino-N-benzylnaphthalene-2-sulfonamide;

6-Acetylamino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Acetylamino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

6-Amino-N-benzylnaphthalene-2-sulfonamide;

6-Amino-N-[4-(tert-butyl)benzyl]naphthalene-2-sulfonamide;

6-Amino-N-(2,3-dimethoxybenzyl)naphthalene-2-sulfonamide;

5-Amino-N-benzylnaphthalene-1-carboxamide;

5-Amino-N-[4-(tert-butyl)benzyl]naphthalene-1-carboxamide;

5-Amino-N-(2,3-dimethoxybenzyl)naphthalene-1-carboxamide.

19. (New) The medicament according to claim 2, wherein the substance is N-[4-(tert-butyl)benzyl]-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide.

20. (New) A method for enhancing an effect of a cancer therapy based on a mode of action of DNA injury in a mammal including a human, which comprises applying a cancer therapy based on the mode of action of DNA injury to a cancer patient, and administering a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

wherein one of R^1 and R^2 represents hydrogen atom and the other represents the formula -X-A wherein A represents hydrogen atom or an acyl group, X represents oxygen atom or NH; one of R^3 and R^4 represents hydrogen atom and the other represents the following formula:



wherein Y represents a sulfonyl group or a carbonyl group, R^5 represents a cyclic group which may be substituted, Z represents a single bond or a C_1 to C_4 alkylene group which may be substituted, or when Z is substituted, said substituent may bind to R^5 to form a ring group, R^6 represents hydrogen atom or a C_1 to C_6 alkyl group which may be substituted, or R^6 may bind to Z or R^5 to form a cyclic group, provided that a compound represented by the following formula:



wherein each of A, Z, R^5 and R^5 has the same meaning as that defined above, is excluded.

21. (New) The method according to claim 20, wherein R^5 is an aromatic ring group which may be substituted.

22. (New) A method for reducing a side effect resulting from a cancer therapy based on the mode of action of DNA injury in a mammal including a human, which comprises applying a cancer therapy based on the mode of action of DNA injury to a cancer patient, and administering a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

wherein one of R^1 and R^2 represents hydrogen atom and the other represents the formula –X-A wherein A represents hydrogen atom or an acyl group, X represents oxgen atom or NH; one of R^3 and R^4 represents hydrogen atom and the other represents the following formula:



wherein Y represents a sulfonyl group or a carbonyl group, R^5 represents a cyclic group which may be substituted, Z represents a single bond or a C_1 to C_4 alkylene group which may be substituted, or when Z is substituted, said substituent may bind to R^5 to form a ring group, R^6 represents hydrogen atom or a C_1 to C_6 alkyl group which may be substituted, or R^6 may bind to Z or R^5 to form a cyclic group, provided that a compound represented by the following formula:



wherein each of A, Z, R^5 and R^5 has the same meaning as that defined above, is excluded, at a dose sufficient to reduce the side effect of the cancer therapy.

23. (New) The method according to claim 22, wherein R^5 is an aromatic ring group which may be substituted.

24. (New) The compound according to claim 10 or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof, wherein R^5 is an aromatic ring group which may be substituted.

25. (New) The compound according to claim 24 or a pharmacologically acceptable salt thereof, or a hydrate thereof or a solvate thereof, wherein A is hydrogen atom, acetyl group or para-toluenesulfonyl group.